Tdam USA Inc. lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 1.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 211,009 shares of the company’s stock after buying an additional 2,557 shares during the period. Merck & Co., Inc. comprises 1.2% of Tdam USA Inc.’s investment portfolio, making the stock its 21st biggest holding. Tdam USA Inc.’s holdings in Merck & Co., Inc. were worth $17,693,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. JJJ Advisors Inc. acquired a new stake in Merck & Co., Inc. during the 2nd quarter valued at $27,000. PRW Wealth Management LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter valued at $41,000. Aspire Private Capital LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter valued at $55,000. Thor Advisors LLC acquired a new stake in Merck & Co., Inc. during the 1st quarter valued at $69,000. Finally, Contravisory Investment Management Inc. grew its holdings in Merck & Co., Inc. by 19.7% during the 2nd quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock valued at $72,000 after buying an additional 141 shares during the last quarter. Institutional investors and hedge funds own 75.34% of the company’s stock.
Shares of MRK stock traded down $0.17 during mid-day trading on Thursday, hitting $83.23. 203,153 shares of the company’s stock were exchanged, compared to its average volume of 9,473,427. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.07. The company has a 50-day simple moving average of $83.37. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $219.45 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.74 and a beta of 0.56.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.64%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.69%.
A number of brokerages have commented on MRK. Citigroup increased their target price on Merck & Co., Inc. from $84.00 to $95.00 and gave the company a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Goldman Sachs Group began coverage on Merck & Co., Inc. in a report on Tuesday, May 28th. They set a “neutral” rating and a $85.00 target price on the stock. Argus increased their target price on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, BMO Capital Markets increased their target price on Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $91.07.
In related news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total value of $18,514,218.74. Following the completion of the transaction, the chief financial officer now directly owns 354,378 shares in the company, valued at $30,274,512.54. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: Economic Reports
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.